Entero Healthcare cuts GLP-1 market share estimate by half
Management revised its GLP-1 market share to 5% from 10% and corrected its FY26 acquisition count during a post-results conference call.
— 3 earlier stories on Entero Healthcare Solutions Ltd. →What's new
- GLP-1 market share estimate halved to 5% from the 10% claimed in February.
- FY26 MedTech acquisition count corrected to three from the four previously reported.
- FY27 guidance targets 23% revenue growth and a 5% EBITDA margin.
Why this matters
Management credibility suffers when basic operational metrics like acquisition counts and market share estimates are revised downward shortly after being reported. These discrepancies suggest a lack of precision in internal reporting that requires close monitoring.
What we're watching
- Whether the 5% EBITDA margin target is met in FY27.
- The sustainability of the 50% EBITDA-to-operating cash flow conversion goal.
- Any further revisions to historical operational data.
The full read
Entero Healthcare’s post-results conference call left investors with a mix of ambitious targets and uncomfortable corrections. Management guided for 23% revenue growth and a 5% EBITDA margin in FY27, while promising a 50% conversion of EBITDA to operating cash flow. The session included two material revisions to prior claims. The company halved its GLP-1 market share estimate to 5% from the 10% cited in February and admitted it closed only three MedTech acquisitions in FY26, not the four previously stated. These inconsistencies raise questions about the accuracy of internal reporting. Management pointed to a network of 100,000 retail pharmacy customers and 3,300 manufacturer partners, but the focus remains on whether the ₹1,000 crore annualised run-rate in the MedTech segment can deliver the promised margins. With ROCE rising to 14.6% from 10.7%, the operational performance is improving, but the accuracy of the reported data is now the primary test.
Questions answered
- What is the new guidance for FY27?
- Management targets 23% revenue growth and a 5% EBITDA margin for FY27. They also aim for at least a 50% conversion of EBITDA to operating cash flow.
- How did the company's GLP-1 market share claim change?
- The company revised its GLP-1 market share down to 5%. This is a reduction from the 10% share management claimed in February.
- What was the discrepancy regarding FY26 acquisitions?
- Management clarified that it closed three MedTech acquisitions in FY26. It had previously reported that four acquisitions were completed.
- What is the current scale of the MedTech business?
- MedTech acquisitions have reached a combined ₹1,000 crore annualised run-rate. Management claims these assets operate with higher-margin commercial models.
- How did operating cash flow and ROCE perform in FY26?
- Operating cash flow for FY26 was ₹96.2 crore. ROCE improved to 14.6% from 10.7% in the previous year.
Story so far
All notes on ENTERO →- 26 May 2026 · 1:28 PM IST Entero Healthcare cuts GLP-1 market share estimate by half
- today Entero Healthcare reports 30% revenue growth in FY26
- today Entero Healthcare revenue grows 29.6% to ₹6,591 crore in FY26
- today Entero Healthcare grows revenue 29.6% to ₹6,591 crore in FY26